Professional Documents
Culture Documents
Genetic Diversity of SCN5a Gene
Genetic Diversity of SCN5a Gene
Research Article
Genetic Diversity of SCN5A Gene and Its Possible Association
with the Concealed Form of Brugada Syndrome Development in
Polish Group of Patients
Beata UziwbBo-gyczkowska,1 Grzegorz Gielerak,1 PaweB Siedlecki,2 and Beata Pajdk3,4
1
Department of Cardiology and Internal Diseases, Military Institute of Medicine, Szaserow Street 128, 04-141 Warsaw 44, Poland
Department of Bioinformatics, Institute of Biochemistry and Biophysics, Polish Academy of Sciences, 02-106 Warsaw, Poland
3
BioVectis/Kucharczyk TE, Pawinskiego 5A, 02-106 Warsaw, Poland
4
Electron Microscopy Platform, Mossakowski Medical Research Centre, Polish Academy of Sciences, 02-106 Warsaw, Poland
2
1. Introduction
About 510% of sudden cardiac death (SCD) cases are caused
mainly by electrical heart diseases [1]. In the recent years, a
special attention has been paid to one of them, the Brugada
Syndrome (BS). The diagnosis of BS is based on ECG criteria
as well as on the clinical picture. Typical BS ECG changes
occur as a result of ion function disorders in the heart,
which are caused by genetic mutations and lead to improper
course mainly of repolarization processes in cardiomyocytes.
Electrocardiographic features of the syndrome are dynamic
and ECG curve is periodically normal; typical BS characteristics disappear, which makes it difficult to diagnose
BS. Concealed form of BS causes underestimation of this
diseases occurrence frequency and a great number of people
remain undiagnosed. Specific pharmacological provocation
2.4. Functional Analysis of SCN5A Variants. An in silico analysis was performed to evaluate the putative functional impact
of the three identified variations (S321Y, S519F, and K974D).
We used the Polymorphism phenotyping-2 (PolyPhen-2)
server [13], which integrates sequence-based and structurebased features to predict amino acid substitution effects
using a nave Bayes classifier. An amino acid change was
classified as probably damaging if its probability score
was greater than 0.85 or as possibly damaging if the
score was between 0.85 and 0.55. To assess the influence
of putative unstructured regions, we used DISOPRED3 [14]
software along with DOMPRED [15] to predict possible
domain boundaries and disordered binding regions. Finally,
we used Phyre [16] for structural feature predictions, mainly
Number of included
patients
35 patients (59.32%)
(i) RBBB complete8
patients (13.6%)
(ii) RBBB incomplete27
patients (45.76%)
History of SCA
7 patients (11.8%)
Unexplained syncopes
SCD amongst family
members under 45
Family history of Brugada
Syndrome
31 patients (52.5%)
Suspected but
nondiagnostic ECG (types
2 and 3)
5 patients (8.5%)
4 patients (6.8%)
16 patients (27.11%)
(i) Type 24 patients
(6.78%)
(ii) Type 312 patients
(20.33%)
3. Results
3.1. Patient Demographics. Study inclusion criteria were met
by 59 patients (22 women and 37 men) (Table 1). Average age
of the group was 31.612.2 years, from 16 to 62 years. Average
age for women was 29.68 10.9 years while, for men, it was
32.8 12.9 years. The majority of patients (72.8%) were under
40.
Echocardiography in all the included patients revealed no
significant organic heart disease.
3.2. Clinical Characteristics of the Group with Positive Result of
Pharmacological Provocation Test. Pharmacological provocation test was carried out on the whole study group.
No significant undesirable effects were observed. None of
the patients met the criteria of discontinuation prior the
scheduled conclusion of the study.
Positive test resulttype 1 ST segment elevation
(Figure 1(a)), which was considered as diagnostic of BS, was
obtained in 7 individuals (11.86%). The other 52 patients
(88.14%) had negative provocation test results (Figure 1(b)).
The group of 7 patients with type 1 ST segment elevation
diagnostic of BS following ajmaline administration consisted
of 6 men (85.7%) and 1 woman (14.3%). Average age of this
group was 36.5 15.2, from 16 to 52 years. The group of
patients with negative test results included 31 men (59.6%)
and 21 women (40.4%). Average age of this group was
30.9 11.7, from 18 to 62 years. No statistically significant
correlation between gender, age, or body mass and ajmaline
test was observed.
As regards the group of 7 individuals with positive
provocation test results, 2 patients had history of SCA (men),
among whom, in 1 person, the diagnosed SCA mechanism
(a)
(b)
Figure 1: (a) 12-lead ECG from a patient with positive test result (before and after test). The configuration of the ST segment elevation in
leads V1 to V3 is a coved type. (b) 12-lead ECG from a patient with negative test result (before and after test).
Exon 2
4 5 6
Exon 7
4 5 6
was present in 182 mRNA position and was related to a nontraslanted mRNA part. The patients with this polymorphism
(a woman and a man) were asymptomatic; pharmacological
provocation test was positive in the man and negative in the
woman.
A new DNA sequence change was also observed at exon
28g of the SCN5A gene in 5 patients. It involved an alteration
in nucleotides in 38531355 position (G>A) of reference
sequence in 6703 mRNA position. The genetic alteration was
present in a nontraslanted part of the exon. The 5 individuals
included 2 men with symptomatic BS and history of SCA.
Moreover, the group included the brother and the father of
the patient with history of SCA, one with a negative and the
other with a positive result of pharmacological provocation
test. The last person with this polymorphism was a man with
asymptomatic BS.
Genotyping exon 28i of the SCN5A gene revealed 4
new polymorphisms localized in a nontraslanted part of the
exon. These changes were found in all the examined persons,
among whom 4 patients had all the 4 genetic variants and 3
patients had two new sequence changes: in 38530974 (C>T)
and 38531102 (C>T) position of reference sequence, while
polymorphism in 38530974 position (C>T) was observed in
all the patients.
Furthermore, analysis of exon 28l of the SCN5A gene
showed a new sequence variant in 38529996 position (C>G)
of reference sequence in 8062 mRNA position. The change
Exon 2 ref.
Exon 2 samp.
Consensus
5
1
11
21
31
41
51
GGTCTGCCCACCCTGCTCTCTGTCCCTGGGCATAGAATCAGGCCCATTGTCTGTGTCTTC
GGTCTGCCCACCCTGCTCTCTGTCCCTGGGCATAGAATCAGGCCCATTGTCTGTGTCTTC
ggtctgcccaccctgctctctgtccctgggcatagaatcaggcccattgtctgtgtcttc
61
71
81
91
101
111
GAGCTTCCCCACAGGCAACGTGAGGAGAGCCTGTGCCCAGAAGCAGGATGAGAAGATGGC
GAGCTTCCCCACAGGCAACGTGAGGAGAGCCTGTGCCCAGAACCAGGATGAGAAGATGGC
Exon 2 ref.
Exon 2 samp. 1
Consensus
cagcttccccacaggcaacgtgaggagagcctgtgcccagaa caggatgagaagatggc
Exon 2 ref.
Exon 2 samp. 1
Consensus
121
131
141
151
161
171
AAACTTCCTATTACCTCGGGGCACCAGCAGCTTCCGCAGGTTCACACGGGAGTCCCTGGC
AAACTTCCTATTACCTCGGGGCACCAGCAGCTTCCGCAGGTTCACACGGGAGTCCCTGGC
aaacttcctattacctcggggcaccagcagcttccgcaggttcacacgggagtccctggc
Exon 2 ref.
Exon 2 samp. 1
Consensus
Exon 2 ref.
Exon 2 samp. 1
Consensus
Exon 2 ref.
Exon 2 samp. 1
Consensus
Exon 2 ref.
Exon 2 samp. 1
Consensus
Exon 2 ref.
Exon 2 samp. 1
Consensus
181
191
201
211
221
231
AGCCATCGAGAAGCGCATGGCAGAGAAGCAAGCCCGCGGCTCAACCACCTTGCAGGAGAG
AGCCATCGAGAAGCGCATGGCGGAGAAGCAAGCCCGCGGCTCAACCACCTTGCAGGAGAG
agccatcgagaagcgcatggc gagaagcaagcccgcggctcaaccaccttgcaggagag
241
251
261
271
281
291
CCGAGAGGGGCTGCCCGAGGAGGAGGCTCCCCGGCCCCAGCTGGACCTGCAGGCCTCCAA
CCGAGAGGGGCTGCCCGAGGAGGAGGCTCCCCGGCCCCAGCTGGACCTGCAGGCCTCCAA
ccgagaggggctgcccgaggaggaggctccccggccccagctggacctgcaggcctccaa
311
321
331
341
351
301
AAAGCTGCCAGATCTCTATGGCAATCCACCCCAAGAGCTCATCGGAGAGCCCCTGGAGGA
AAAGCTGCCAGATCTCTATGGCAATCCACCCCAAGAGCTCATCGGAGAGCCCCTGGAGGA
aaagctgccagatctctatggcaatccaccccaagagctcatcggagagcccctggagga
361
371
381
391
401
411
CCTGGACCCCTTCTATAGCACCCAAAAGGTGACTACCACCCACCTCCAGCCCTGCCTACC
CCTGGACCCCTTCTATAGCACCCAAAAGGTGACTACCACCCACCTCCAGCCCTGCCTACC
cctggaccccttctatagcacccaaaaggtgactaccacccacctccagccctgcctacc
421
431
CTTCTGTGCAACTCCC
CTTCTGTGCAACTCCC
cctctgtgcaactccc
441
451
461
471
Figure 3: Sequence alignment of SCN5 exon 2 reference (WT) and MT amplicon detected in sample 5 (pos. 38614716 heterozygote A>G,
exon, amino acid pos. 29, polymorphism rs6599230; pos. 38614815 heterozygote G>C, exon, pos. 182 in mRNA, nontraslanted region). White
color shows changed nucleotides.
ex 8,
C>A
ex 12,
C>T
ex 17,
G>T
S/Y
S/F
K/D
C
N
321
aa number
519
974
2015
Figure 4: Schematic illustration of Nav1.5, showing the location of the novel putative amino acid changes.
N-terminal
Extracellular
Cytoplasmic
133
180
193
243
247
374
389
737
751
798
808
861
915
S1
S2
S3
S4
S5
S6
S7
S8
S9
S10
S11
S12
S13
150
160
210
220
273
359
416
718
770
781
833
837
942 Membrane
C-terminal
(a)
This mutation is predicted to be possibly damaging with a score of 0.667 (sensitivity: 0.86; specificity: 0.91)
S321Y
HumDiv
0.00
0.20
0.40
0.60
0.80
1.00
This mutation is predicted to be possibly damaging with a score of 0.635 (sensitivity: 0.80; specificity: 0.84)
HumVar
0.00
0.20
0.40
0.60
0.80
0.60
0.80
1.00
This mutation is predicted to be probably damaging with a score of 0.992 (sensitivity: 0.49; specificity: 0.95)
HumVar
0.00
0.20
0.40
0.60
0.80
1.00
This mutation is predicted to be possibly damaging with a score of 0.775 (sensitivity: 0.85; specificity: 0.92)
K974D
0.00
HumDiv
0.20
0.40
0.60
0.80
1.00
This mutation is predicted to be possibly damaging with a score of 0.516 (sensitivity: 0.82; specificity: 0.81)
HumVar
0.00
0.20
0.40
0.60
0.80
1.00
(b)
Confidence score
0.40
Na trans assoc
9531215
0.8
HumDiv
S519F
0.20
DUF3451
461668
1.00
This mutation is predicted to be probably damaging with a score of 0.997 (sensitivity: 0.41; specificity: 0.98)
0.00
Ion trans
159412
0.6
0.4
0.2
200
400
600
800
1000
Amino acid position
1200
1400
(c)
Figure 5: (a) Prediction of transmembrane, extracellular in cytoplasmic regions in SCN5a protein. Location of the three new variants is
depicted as orange dots. (b) Prediction of functional effects of nonsynonymous mutations done in PolyPhen2 software. All three variants
have two scores from HumDiv (genomic oriented) and HumVar (diagnostic oriented). (c) Prediction of intrinsically disordered regions in
SCN5a (11400AA) done by DISOPRED3. Domain organisation shown with respect to disordered regions. Orange color marks putative
binding sites. High confidence score indicated better chance of unstructured fragment.
7
MSSCP analysis showed presence of 2 new genetic variants at exon 6 of the SCN5A gene within the intron in 7
patients out of 8. The first involved a change in nucleotides
in 38595390 position (C>G) of reference sequence. The
second mutation was a change in 38595384 position (C>G)
of reference sequence. These DNA variants were observed in
all the examined patients apart from one individual who was
asymptomatic and had negative result of pharmacological
provocation test. At exon 7 of the SCN5A gene, a DNA
sequence variant within the intron (pos. 38591480, C>G) was
identified in 4 patients out of 6 with positive ajmaline provocation test. Moreover, 3 patients from this group had symptomatic BS and had an implanted cardioverter-defibrillator
either due to history of SCA or due to unexplained syncopes.
Concurrently, this polymorphism was confirmed in neither
of the patients with negative results of provocation test. The
results of MSSCP genotyping of 41 amplicons representing
SCN5A gene are summarized in Table 2. Additionally, Table 3
contains the list of intronic alterations and exchanges in
noncoding regions along with short stretches of sequence
alignments (WT > MT).
4. Discussion
The major gene related to BS is the SCN5A gene. Despite
the great development in molecular studies, it is estimated
that mutations in the SCN5A gene cause only about 18
30% of BS cases [17]. These mutations are more common
in familial cases of the disease than in sporadic ones [18].
Negative results of genetic studies do not exclude causal
gene mutations. Neither diagnosis nor prognosis of BS can
be based on genetic test results. In the presented work, a
molecular analysis of the whole SCN5A gene was carried out
with respect to patients with positive provocation test (apart
from 1 person who failed to give their informed consent)
as well as their family members (1st degree of kinship) who
gave their informed consent. Due to both low predicted BS
incidence in the Polish population (lack of accurate data) and
a considerably low percentage of the known genetic changes
being the underlying cause of the disease (1830% as above),
the work was limited only to analyzing the occurrence of
the known mutations. The molecular study of the 28 exons
and short exon/intron fragments of SCN5 gene was carried
out including also the alterations in the sequence of the few
noncoding regions of the gene (introns). In this study, the new
genetic variants were found both at exons and at introns. It is
a commonly accepted fact that the effects of DNA sequence
change depend on their location in the gene. However, all too
often, it is assumed that only genetic alterations in the coding
sequences, that is, at exons, have an impact on the clinical
course of the disease. Recent studies and findings have shown
that intronic mutations may play a major role in the splicing
process, alter its course, lead to coding sequence abnormalities, and consequently influence the structure and function
of the encoded proteins. Numerous data reported in scientific
papers show that both intronic and exonic alterations may
result in an aberrant splicing process, leading to the formation
of abnormal proteins, which, in turn, affects the severity of
Asymptomatic
Negative pharmacological
provocation test
Father of the patient with
diagnosed BS
Patient 1
Patient 2
Patient 3
8
BioMed Research International
Asymptomatic
Positive pharmacological
provocation test
Brother of the patient with
diagnosed BS
Asymptomatic
Positive pharmacological
provocation test
Father of the patient with
diagnosed BS
Unexplained syncopes
Positive pharmacological
provocation test
Diagnosed BS
Patient 4
Patient 5
Patient 6
Table 2: Continued.
Genetic alterations in DNA sequences of SCN5 amplicons
(reference sequence ref|NT 022517.17|Hs3 22673)
Amplicon 4: pos. 38604076 G>T, intron
Amplicon 6: pos. 38595390 homozygote C>G, intron
pos. 38595384 homozygote C>G, intron
Amplicon 12a: pos. 38585541 C>T exon, amino acid pos. 519, S>F
pos. 38585647 homozygote A>T, intron
Amplicon 22: pos. 38544050, heterozygote C/T, intron
Amplicon 24: pos. 38547178 heterozygote A/G, intron, polymorphism rs41312393
Amplicon 28c: pos. 38592406 T>C, exon, amino acid pos. 1818, D>D, rs1805126
Amplicon 28f: pos. 38531693 A>G, exon, mRNA position 6365, near 3 UTR, nontraslanted region, rs7429945
Amplicon 28g: pos. 38531355 G>A, exon, mRNA position 6703, near 3 UTR, nontraslanted region
Amplicon 28i: pos. 38530974 C>T, exon, mRNA position 7084, near 3 UTR, nontraslanted region
pos. 38531102 C>T, exon, mRNA position 6956, near 3 UTR, nontraslanted region
Amplicone 2: pos. 38614716 A>G, exon, amino acid pos. 29, A>A, polymorphism rs6599230
pos. 38614815, G>C, exon, mRNA pos.182, nontraslanted region
Amplicone 4: pos. 38604075 homozygote G>T, intron
Amplicon 6: pos. 38595390 homozygote C>G, intron
pos. 38595384 homozygote C>G, intron
Amplicon 17a: pos. 38562732 G>T, amino acid pos. 974, K>D
Amplicon 17b: pos. 38562471 homozygote A>G, amino acid pos. 1061, E>E, polymorphism rs7430407
Amplicon 24: pos. 38547178 heterozygote A>G, intron, polymorphism rs41312393
Amplicon 27: pos. 38536074 deletion T, intron
pos. 38536077 homozygote T>A, intron
Amplicon 28c: pos. 38592406 T>C, exon, amino acid pos. 1818, D>D, rs1805126
Amplicon 28f: pos. 38531693 A>G, exon, mRNA position 6365, near 3 UTR, nontraslanted region, rs7429945
Amplicon 28g: pos. 38531355 G>A, exon, mRNA position 6703, near 3 UTR, nontraslanted region
Amplicon 28i: pos. 38530853 deletion C, exon, mRNA pos. 7205, near 3 UTR, nontraslanted region
pos. 38530856 insertion A, exon, mRNA pos. 7202, near 3 UTR, nontraslanted region
pos. 38530974 C>T, exon, mRNA pos. 7084, near 3 UTR, nontraslanted region
pos. 38531102 C>T, exon, mRNA pos. 6956, near 3 UTR, nontraslanted region
Amplicon 28k: pos. 38530279 T>C, exon, mRNA pos. 7779, 3 UTR, nontraslanted region, polymorphism rs41315485
Amplicon 4: pos. 38603806, insertion A, intron
pos. 38603801 homozygote T>A, intron
Amplicon 6: pos. 38595390 C>G, intron
pos. 38595384 homozygote C>G, intron
Amplicon 7: pos. 38591480 C>G, intron
Amplicon 28f: pos. 38531693 A>G, exon, mRNA position 6365, near 3 UTR, nontraslanted region, rs7429945
Amplicon 28i: pos. 38530853 deletion C, exon, mRNA pos. 7205, near 3 UTR, nontraslanted region
pos. 38530856 insertion A, exon, mRNA pos. 7202, near 3 UTR, nontraslanted region
pos. 38530974 C>T, exon, mRNA pos. 7084, near 3 UTR, nontraslanted region
pos. 38531102 C>T, exon, mRNA pos. 6956, near 3 UTR, nontraslanted region
Amplicon 28k: pos. 38530279 T>C, exon, mRNA pos. 7779, 3 UTR, nontraslanted region, polymorphism rs41315485
Unexplained syncopes
Positive pharmacological
provocation test
Diagnosed BS
Asymptomatic
Positive pharmacological
provocation test
Patient 7
Patient 8
Table 2: Continued.
Genetic alterations in DNA sequences of SCN5 amplicons
(reference sequence ref|NT 022517.17|Hs3 22673)
Amplicon 2: pos. 38614716, A>G, amino acid pos. 29, A>A, polymorphism rs6599230
pos. 38614815, G>C, exon, mRNA pos.182, nontraslanted region
Amplicon 4: pos. 38603806, insertion A, intron
pos. 38603801 homozygote T>A, intron
Amplicon 6: pos. 38595390 C>G, intron
pos. 38595384 homozygote C>G, intron
Amplicon 17a: pos. 38562732 G>T, amino acid pos. 974, K>D
Amplicon 24: pos. 38547178 heterozygote A/G, intron, polymorphism rs41312393
Amplicon 28f: pos. 38531693 A>G, exon, mRNA position 6365, near 3 UTR, nontraslanted region, rs7429945
Amplicon 28i: pos. 38530853 deletion C, exon, mRNA pos. 7205, near 3 UTR, nontraslanted region
pos. 38530856 insertion A, exon, mRNA pos. 7202, near 3 UTR, nontraslanted region
pos. 38530974 C>T, exon, mRNA pos. 7084, near 3 UTR, nontraslanted region
pos. 38531102 C>T, exon, mRNA pos. 6956, near 3 UTR, nontraslanted region
Amplicon 28k: pos. 38530279 T>C, exon, mRNA pos. 7779, 3 UTR, nontraslanted region, polymorphism rs41315485
Amplicon 4: pos. 38603806, insertion A, intron
pos. 38603801 homozygote T>A, intron
Amplicon 6: pos. 38595390 C>G, intron
pos. 38595384 homozygote C>G, intron
Amplicon 7: pos. 38591480 C>G, intron
Amplicon 28f: pos. 38531693 A>G, exon, mRNA position 6365, near 3 UTR, nontraslanted region, rs7429945
Amplicon 28i: pos. 38530853 deletion C, exon, mRNA pos. 7205, near 3 UTR, nontraslanted region
pos. 38530856 insertion A, exon, mRNA pos. 7202, near 3 UTR, nontraslanted region
pos. 38530974 C>T, exon, mRNA pos. 7084, near 3 UTR, nontraslanted region
pos. 38531102 C>T, exon, mRNA pos. 6956, near 3 UTR, nontraslanted region
Amplicon 28k: pos. 38530279 T>C, exon, mRNA pos. 7779, 3 UTR, nontraslanted region, polymorphism rs41315485
Amplicon 28l: pos. 38529996 homozygote C>G, exon, mRNA pos. 8062, near 3 UTR, nontraslanted region
10
BioMed Research International
11
Table 3: The list of intronic alterations and exchanges in noncoding regions along with short stretches of sequences alignments (WT > MT).
Amplicon
Position
Pos. 38631119
Detected
polymorphism
(WT > MT)
Localization
G>A
Exon,
nontraslanted
region
1
11
Amp. 1 WT CGCAGGCTCAGCGGCC
Amp. 1 MT CGCAGGCTCAACGGCC
cgcaggctca cggcc
Consensus
Exon,
nontraslanted
region
1
11
Amp. 2 WT CCAGAAGCAGGATGAG
Amp. 2 MT CCAGAACCAGGATGAG
ccagaa caggatgag
Consensus
Pos. 38614815
G>C
Pos. 38603806
Pos. 38603801
Insertion A
T>A
Pos. 38604075
G>T
Intron
Intron
Amp. 4 WT
Amp. 4 MT
Consensus
Amp. 4 WT
Amp. 4 MT
Consensus
Pos. 38604076
Pos. 38595390
Pos. 38595384
Pos. 38591480
G>T
G>C
G/C
C>G
Intron
Intron
Intron
Pos. 38589643
Insertion A
Intron
Amp. 6 WT
Amp. 6 MT
Pos. 38585647
A>T
Intron
24
27
Pos. 38544050
Pos. 38538672
Pos. 38536074
Pos. 38536077
C>T
A>G
Deletion T
T>A
Intron
Intron
Intron
1
11
CCTCTGACTGTGTGTC
CCTCTCACTGTCTGTC
Amp. 7 WT
Amp. 7 MT
1
11
GAACAAGCACGGGGTC
GAACAAGGACGGGGTC
gaacaag acggggtc
Amp. 8 WT
Amp. 8 MT
Amp. 12 WT
Amp. 12 MT
Consensus
22
1
11
AGCACTGGCCTGGCAGT
AGCACTTGCCTGGCAGT
agcact gcctggcagt
Consensus
Consensus
12
ggaaggggg cttg g
1
11
Amp. 4 WT TGGTAGCACTGGCCTGG
Amp. 4 MT TGGTAGCACTGTCCTGG
Consensus tggtagcactg cctgg
Consensus
1
11
GGAAGGGGG-CTTGTG
GGAAGGGGGACTTGAG
1
11
CTGGGTA-TGTGGCA
CTGGGTAATGTGGCA
ctgggta tgtggca
1
11
GCCAGTGGCACAAAAG
GCCAGTGGCTCAAAAG
gccagtggc caaaag
Consensus
1
11
CCATTTCTACTTTG
CCATTTTTACTTTG
ccattt tactttg
Amp. 24 WT
Amp. 24 MT
1
11
GCCAAGCAACCAGG
GCCAAGCAGCCAGG
Consensus
gccaagca ccagg
Amp. 22 WT
Amp. 22 MT
1
11
Amp. 27 WT CCTGCTGAGCACTTTC
Amp. 27 MT CCAGC-GAGCACTTTC
Consensus
cc gc gagcactttc
12
Amplicon
28f
28g
Position
Pos. 38531693
Pos. 38531355
Detected
polymorphism
(WT > MT)
Localization
A>G
Exon, near
3 UTR,
nontraslanted
region
G>A
Exon, near
3 UTR,
nontraslanted
region
Consensus
Amp. 28g WT
Amp. 28g MT
Consensus
Amp. 28i WT
Amp. 28i MT
Consensus
28i
28k
28l
Pos. 38530853
Pos. 38530856
Pos. 38530974
Pos. 38531102
Pos. 38530279
Pos. 38529996
Deletion C
insertion A
C>T
C>T
Exon, near
3 UTR,
nontraslanted
region
T>C
3 UTR,
nontraslanted
region
C>G
Exon, near
3 UTR,
nontraslanted
region
1
11
GGCCTCAGCCCC
GGCCTCGGCCCC
ggcctc gcccc
1
11
CAAAGCAGAAGTGGAA
CAAAGCAAAAGTGGAA
caaagca aagtggaa
1
11
ATCGGAAGAGAG
AT-GGAAGAGAG
at ggaagagag
1
11
Amp. 28i WT CCCAGCCAGCCAAmp. 28i MT
CCCAGCCAGCCAA
Consensus
cccagccagcca
1
11
Amp. 28i WT
CCTTTTCTTCCCCTCCTG
Amp. 28i MT
CCTTTTTTTCCCCTCCTG
cctttt ttcccctcctg
Consensus
1
11
Amp. 28i WT
GGCCCCCTATTGTCTCCA
Amp. 28i MT
GGCCCCCTATTGTTTCCA
Consensus
ggccccctattgt tcca
Amp. 28k WT
Amp. 28k MT
1
11
TCTCCCATGGAGC
TCTCCCACGGAGC
Consensus
tctccca ggagc
Amp. 28l WT
Amp. 28l MT
1
11
CAGCGACATTTCTC
CAGCGAGATTTCTC
Consensus
cagcga atttctc
5. Conclusions
New genetic variants/polymorphisms in the SCN5A gene
are present in patients with concealed forms of Brugada
Syndrome, yet their role in pathogenesis requires further
studies.
Conflict of Interests
The authors do not report any conflict of interests regarding
the publication of this paper.
References
[1] S. G. Priori, E. Aliot, C. Blomstrom-Lundqvist et al., Task force
on sudden cardiac death of the European Society of Cardiology,
European Heart Journal, vol. 22, pp. 13741450, 2001.
13
[2] Q. Chen, G. E. Kirsch, D. Zhang et al., Genetic basis and
molecular mechanism for idiopathic ventricular fibrillation,
Nature, vol. 392, no. 6673, pp. 293296, 1998.
[3] http://www.fsm.it/uo-int.php?id=7516.
[4] J. D. Kapplinger, D. J. Tester, M. Alders et al., An international
compendium of mutations in the SCN5A-encoded cardiac
sodium channel in patients referred for Brugada syndrome
genetic testing, Heart Rhythm, vol. 7, no. 1, pp. 3346, 2010.
[5] T. Zimmer and R. Surber, SCN5A channelopathiesan update
on mutations and mechanisms, Progress in Biophysics and
Molecular Biology, vol. 98, no. 2-3, pp. 120136, 2008.
[6] E. Schulze-Bahr, L. Eckardt, G. Breithardt et al., Sodium channel gene (SCN5A) mutations in 44 index patients with Brugada
syndrome: different incidences in familial and sporadic disease,
Human Mutation, vol. 21, no. 6, pp. 651652, 2003.
[7] B. London, M. Michalec, H. Mehdi et al., Mutation in glycerol3-phosphate dehydrogenase 1-like gene (GPD1-L) decreases
cardiac Na+ current and causes inherited arrhythmias, Circulation, vol. 116, no. 20, pp. 22602268, 2007.
[8] C. Antzelevitch, G. D. Pollevick, J. M. Cordeiro et al., Loss-offunction mutations in the cardiac calcium channel underlie a
new clinical entity characterized by ST-segment elevation, short
QT intervals, and sudden cardiac death, Circulation, vol. 115,
no. 4, pp. 442449, 2007.
[9] B. Benito, O. Campuzano, R. Ishac et al., Role of genetic testing
in risk stratification of Brugada syndrome, Heart Rhythm, vol.
6, no. 5, supplement, article S102, 2009.
[10] E. Lizotte, M. J. Junttila, M. P. Dube et al., Genetic modulation
of brugada syndrome by a common polymorphism, Journal of
Cardiovascular Electrophysiology, vol. 20, no. 10, pp. 11371141,
2009.
[11] Q. Wang, Z. Li, J. Shen, and M. T. Keating, Genomic organization of the human SCN5A gene encoding the cardiac sodium
channel, Genomics, vol. 34, no. 1, pp. 916, 1996.
[12] R. Kaczanowski, L. Trzeciak, and K. Kucharczyk, Multitemperature single-strand conformation polymorphism, Electrophoresis, vol. 22, pp. 35393545, 2001.
[13] I. A. Adzhubei, S. Schmidt, L. Peshkin et al., A method and
server for predicting damaging missense mutations, Nature
Methods, vol. 7, no. 4, pp. 248249, 2010.
[14] J. J. Ward, J. S. Sodhi, L. J. McGuffin, B. F. Buxton, and D. T.
Jones, Prediction and functional analysis of native disorder in
proteins from the three kingdoms of life, Journal of Molecular
Biology, vol. 337, no. 3, pp. 635645, 2004.
[15] D. W. A. Buchan, S. M. Ward, A. E. Lobley, T. C. O. Nugent,
K. Bryson, and D. T. Jones, Protein annotation and modelling
servers at University College London, Nucleic Acids Research,
vol. 38, no. 2, pp. W563W568, 2010.
[16] L. A. Kelley and M. J. E. Sternberg, Protein structure prediction
on the Web: a case study using the Phyre server, Nature
Protocols, vol. 4, no. 3, pp. 363371, 2009.
[17] C. Antzelevitch, Brugada syndrome, Pacing and Clinical Electrophysiology, vol. 29, no. 10, pp. 11301159, 2006.
[18] E. Schulze-Bahr, L. Eckardt, G. Breithardt et al., Sodium
channel gene (SCN5A) mutations in 44 index patients with Brugada syndrome: different incidences in familial and sporadic
disease., Human mutation, vol. 21, no. 6, pp. 651652, 2003.
[19] M. Vatta, Intronic variants and splicing errors in cardiovascular diseases, Heart Rhythm, vol. 6, no. 2, pp. 219220, 2009.
[20] B. Benito, O. Campuzano, R. Ishac et al., Role of genetic testing
in risk stratification of Brugada syndrome, Heart Rhythm, vol.
6, supplement 5, p. S102, 2009.
MEDIATORS
of
INFLAMMATION
The Scientific
World Journal
Hindawi Publishing Corporation
http://www.hindawi.com
Volume 2014
Gastroenterology
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com
Volume 2014
Journal of
Diabetes Research
Volume 2014
Volume 2014
Volume 2014
International Journal of
Journal of
Endocrinology
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com
Disease Markers
Volume 2014
Volume 2014
PPAR Research
Hindawi Publishing Corporation
http://www.hindawi.com
Volume 2014
Volume 2014
Journal of
Obesity
Journal of
Ophthalmology
Hindawi Publishing Corporation
http://www.hindawi.com
Volume 2014
Evidence-Based
Complementary and
Alternative Medicine
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com
Volume 2014
Volume 2014
Journal of
Oncology
Hindawi Publishing Corporation
http://www.hindawi.com
Volume 2014
Volume 2014
Parkinsons
Disease
Computational and
Mathematical Methods
in Medicine
Hindawi Publishing Corporation
http://www.hindawi.com
Volume 2014
AIDS
Behavioural
Neurology
Hindawi Publishing Corporation
http://www.hindawi.com
Volume 2014
Volume 2014
Volume 2014